While these findings reveal that combining BRAF and BCL-XL inhibitors represents a promising therapeutic approach for BRAFV600E CRC, the clinical use of BCL-XL inhibitors is currently limited by their on-target toxicity of thrombocytopenia [30, 31]. The gene discussed is BCL2L1; the disease is Thrombocytopenia.